Patents by Inventor Paul R. Hinton

Paul R. Hinton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11344621
    Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: May 31, 2022
    Assignee: Abbvie, Inc.
    Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Hua Ying, Maria A. Argiriadi, Carolyn A. Cuff, Paul R. Hinton, Shankar Kumar, Terry L. Melim, Yan Chen
  • Publication number: 20200308290
    Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.
    Type: Application
    Filed: June 11, 2020
    Publication date: October 1, 2020
    Inventors: Yoshiko AKAMATSU, Fiona A. HARDING, Paul R. HINTON, Olivia Jennifer RAZO, Mengli XIONG, Shiming YE
  • Publication number: 20190008966
    Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
    Type: Application
    Filed: August 27, 2018
    Publication date: January 10, 2019
    Applicant: AbbVie Inc.
    Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Hua Ying, Maria A. Argiriadi, Carolyn A. Cuff, Paul R. Hinton, Shankar Kumar, Terry L. Melim, Yan Chen
  • Patent number: 10150814
    Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with improved potency and efficacy in activation of complement-dependent cytotoxicity.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: December 11, 2018
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Paul R. Hinton, Veronica Juan
  • Patent number: 10086076
    Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: October 2, 2018
    Assignee: AbbVie Inc.
    Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Hua Ying, Maria A. Argiriadi, Carolyn A. Cuff, Paul R. Hinton, Shankar Kumar, Terry L. Melim, Yan Chen
  • Publication number: 20180251565
    Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with altered affinity to Fc receptors.
    Type: Application
    Filed: February 22, 2018
    Publication date: September 6, 2018
    Inventors: Fiona A. HARDING, Paul R. HINTON, Olivia Jennifer RAZO, Mengli XIONG, Shiming YE
  • Publication number: 20170340737
    Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
    Type: Application
    Filed: March 13, 2017
    Publication date: November 30, 2017
    Inventors: Chengbin WU, Richard W. DIXON, Jonathan P. BELK, Hua YING, Maria A. ARGIRIADI, Carolyn A. CUFF, Paul R. HINTON, Shankar KUMAR, Terry L. MELIM, Yan CHEN
  • Publication number: 20170233481
    Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.
    Type: Application
    Filed: May 3, 2017
    Publication date: August 17, 2017
    Applicant: AbbVie Biotherapeutics Inc.
    Inventors: Yoshiko AKAMATSU, Fiona A. HARDING, Paul R. HINTON, Olivia Jennifer RAZO, Mengli XIONG, Shiming YE
  • Patent number: 9592293
    Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: March 14, 2017
    Assignee: AbbVie Inc.
    Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
  • Publication number: 20160137732
    Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with improved potency and efficacy in activation of complement-dependent cytotoxicity.
    Type: Application
    Filed: June 27, 2014
    Publication date: May 19, 2016
    Inventors: Paul R. HINTON, Veronica JUAN
  • Publication number: 20150010539
    Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 8, 2015
    Applicant: AbbVie Biotherapeutics Inc.
    Inventors: YOSHIKO AKAMATSU, FIONA A. HARDING, PAUL R. HINTON, MENGLI XIONG, OLIVIA JENNIFER RAZO, SHIMING YE
  • Publication number: 20140377253
    Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with altered affinity to Fc receptors.
    Type: Application
    Filed: March 14, 2014
    Publication date: December 25, 2014
    Applicant: ABBVIE BIOTHERAPEUTICS INC.
    Inventors: Fiona A. HARDING, Paul R. HINTON, Mengli XIONG, Olivia Jennifer RAZO, Shiming YE
  • Publication number: 20140186377
    Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.
    Type: Application
    Filed: November 26, 2013
    Publication date: July 3, 2014
    Applicant: AbbVie, Inc.
    Inventors: Jijie Gu, Charles W. Hutchins, Rong-Rong Zhu, Jianwei Shen, Maria C. Harris, Eileen Belanger, Tariq Ghayur, Paul R. Hinton, Veronica M. Juan, John Mankovich, Junjian Liu
  • Publication number: 20140178332
    Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.
    Type: Application
    Filed: January 13, 2014
    Publication date: June 26, 2014
    Applicant: ABBVIE INC.
    Inventors: Susan E. Lacy, Emma Fung, Jonathan P. Belk, Richard W. Dixon, Michael Roguska, Paul R. Hinton, Shankar Kumar
  • Publication number: 20140099313
    Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
    Type: Application
    Filed: December 9, 2013
    Publication date: April 10, 2014
    Applicant: ABBVIE INC.
    Inventors: Chengbin WU, Richard W. DIXON, Jonathan P. BELK, Maria A. ARGIRIADI, Hua YING, Carolyn A. CUFF, Terry L. MELIM, Shankar KUMAR, Paul R. HINTON, Yan CHEN
  • Patent number: 8629257
    Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.
    Type: Grant
    Filed: April 19, 2010
    Date of Patent: January 14, 2014
    Assignee: Abbvie Inc.
    Inventors: Susan E. Lacy, Emma Fung, Jonathan P. Belk, Richard W. Dixon, Michael Roguska, Paul R. Hinton, Shankar Kumar
  • Patent number: 8624007
    Abstract: The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: January 7, 2014
    Assignee: Abbvie Biotherapeutics Inc.
    Inventors: Paul R. Hinton, Naoya Tsurushita
  • Patent number: 8604177
    Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: December 10, 2013
    Assignee: AbbVie Inc.
    Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
  • Publication number: 20110183412
    Abstract: The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.
    Type: Application
    Filed: March 31, 2010
    Publication date: July 28, 2011
    Applicant: Facet Biotech Corpration
    Inventors: Paul R. Hinton, Naoya Tsurushita
  • Publication number: 20110165066
    Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
    Type: Application
    Filed: March 8, 2011
    Publication date: July 7, 2011
    Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen